Biogen Idec posted a net income of $294.6m for the second quarter 2010, or $1.12 per diluted share, compared $144.8m, or $0.49 per diluted share, for the comparable period in 2009.
Biogen Idec has reported basic earnings per share $1.13 as compared to $0.49, prior year.
For the six months ended June 30, 2010, the biotechnology firm has posted a net income of $514.6m or $1.91 per diluted share, compared to $391.4m, or $1.33 per diluted share, for the year ago period.
Revenue was $2,3bn compared to $2.1bn for the year ago period.
George Scangos, CEO of Biogen Idec, said: “Biogen Idec had a solid second quarter. Our charge now is to build on the quarter, aggressively execute our marketing plans for Avonex, complete the patient and risk stratification strategy for Tysabri, move the late-stage pipeline forward rapidly, and rationalize the R&D portfolio.
“We have the potential to launch five new products in the next three years. I’m excited about the opportunities ahead and eager to address our challenges head-on and work with the management team and Board to drive Biogen Idec to achieve its full potential.”